Fluorothymidine F-18

OTHER10 trials

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdult Solid NeoplasmClear Cell Renal Cell CarcinomaEstrogen Receptor PositiveGastric AdenocarcinomaHER2/Neu NegativeMale Breast Carcinoma

Early Phase 1

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

Active, not recruitingNCT03422731

City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2018-02-15End: 2026-11-06Updated: 2026-06-08

Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

WithdrawnNCT03613259

OHSU Knight Cancer InstituteStage IIA Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma +3

Start: 2020-06-01End: 2022-06-01Updated: 2020-06-09

Phase 1

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

CompletedNCT00499135

National Cancer Institute (NCI)Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma +2

Start: 2007-05-22End: 2014-05-14Updated: 2017-10-10

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

CompletedNCT00880074

M.D. Anderson Cancer CenterMalignant Neoplasm

Start: 2009-04-09End: 2022-02-04Updated: 2023-06-26

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Active, not recruitingNCT01251874

National Cancer Institute (NCI)Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7 +2

Start: 2010-11-22End: 2026-11-19Updated: 2026-05-22

Phase 2

Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction

CompletedNCT00062374

National Cancer Institute (NCI)Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer +1

Start: 2003-06-30End: 2011-06-30Updated: 2017-07-06

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Active, not recruitingNCT02392429

National Cancer Institute (NCI)Acute Myeloid Leukemia

Start: 2016-04-20End: 2027-02-13Updated: 2026-05-28

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

TerminatedNCT04221438

ECOG-ACRIN Cancer Research GroupMelanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 +3

Start: 2021-09-22End: 2025-01-31Updated: 2026-08-06

Unknown Phase

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

CompletedNCT01928186

University of WashingtonEstrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma +7

Start: 2011-09-30End: 2015-07-20Updated: 2018-05-15

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

CompletedNCT02167204

University of WashingtonMetastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm, Recurrent Brain Neoplasm

Start: 2012-11-30End: 2019-01-21Updated: 2020-01-13

Related Papers

Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).

Journal of Clinical Oncology2014-05-2016 citations